Participated · Series A · Jan 2022

Caeli Nova develops patented breathing technology aimed at improving human safety and performance, principally through its launch product Cordillera, an advanced aircraft emergency oxygen system. Cordillera is designed to overcome limitations of existing aircraft oxygen systems, improve oxygenation at altitude, and enable airlines to fly more direct routes, reducing costs and carbon emissions. The company was founded in 2018 and operates from offices in the UK and Switzerland with a team of 40 medical and aerospace specialists. Caeli Nova aims to install Cordillera onto its first aircraft during 2022 and will use the new financing to further enhance the technology. The startup also intends to explore applications of its breathing technology in clinical and hospital settings. Financially, the company has closed a €7.7 million Series A to advance product development and initial market installations.